OT10 Stock Overview
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Orchard Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.60 |
| 52 Week High | US$15.60 |
| 52 Week Low | US$4.02 |
| Beta | 0.55 |
| 1 Month Change | -0.68% |
| 3 Month Change | -0.68% |
| 1 Year Change | 137.40% |
| 3 Year Change | -69.33% |
| 5 Year Change | n/a |
| Change since IPO | -88.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| OT10 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | 137.4% | -22.4% | 2.2% |
Return vs Industry: OT10 exceeded the German Biotechs industry which returned -26.9% over the past year.
Return vs Market: OT10 exceeded the German Market which returned -0.9% over the past year.
Price Volatility
| OT10 volatility | |
|---|---|
| OT10 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OT10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OT10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | Bobby Gaspar | www.orchard-tx.com |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Orchard Therapeutics plc Fundamentals Summary
| OT10 fundamental statistics | |
|---|---|
| Market cap | €348.84m |
| Earnings (TTM) | -€66.92m |
| Revenue (TTM) | €20.04m |
17.4x
P/S Ratio-5.2x
P/E RatioIs OT10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OT10 income statement (TTM) | |
|---|---|
| Revenue | US$21.84m |
| Cost of Revenue | US$79.52m |
| Gross Profit | -US$57.68m |
| Other Expenses | US$15.24m |
| Earnings | -US$72.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | -264.11% |
| Net Profit Margin | -333.90% |
| Debt/Equity Ratio | 31.9% |
How did OT10 perform over the long term?
See historical performance and comparison